Albireo, An Ipsen Company
Clinical trials sponsored by Albireo, An Ipsen Company, explained in plain language.
-
New drug could delay liver transplants in kids with rare bile duct disease
Disease control OngoingThis study tests a drug called odevixibat in children with biliary atresia, a rare liver disease where bile ducts are blocked. All children have already had a Kasai surgery to help bile flow. The goal is to see if odevixibat can delay or prevent the need for a liver transplant an…
Phase: PHASE3 • Sponsor: Albireo, an Ipsen Company • Aim: Disease control
Last updated May 26, 2026 08:21 UTC
-
New hope for kids with rare liver disease: drug may delay transplant
Disease control ENROLLING_BY_INVITATIONThis study tests the long-term safety and effectiveness of odevixibat in children with biliary atresia, a rare liver disease. The main goal is to see if the drug helps children stay alive without needing a liver transplant. About 180 children who completed a previous study will t…
Phase: PHASE3 • Sponsor: Albireo, an Ipsen Company • Aim: Disease control
Last updated May 11, 2026 20:51 UTC